<DOC>
	<DOC>NCT00307398</DOC>
	<brief_summary>A 48 month study of posterior juxtascleral administrations of Anecortave Acetate 15 or 30 mg or sham administration every 6 months.</brief_summary>
	<brief_title>Anecortave Acetate Risk-Reduction Trial (AART)</brief_title>
	<detailed_description />
	<mesh_term>Anecortave</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Dry AMD study eye, Wet AMD nonstudy eye. Other protocoldefined inclusion criteria may apply. Age Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>AMD</keyword>
	<keyword>Dry AMD</keyword>
	<keyword>Drusen</keyword>
	<keyword>CNV</keyword>
</DOC>